Alex Zhavoronkov Maps a Path Forward for Longevity Medicine
Published in Artificial Intelligence, Drugs development & discovery, Organisations.
For thousands of years, humanity has pursued the dream of extending life. Across civilizations, the search for an “elixir of life” has appeared in mythology, literature, and cultural traditions, reflecting a universal desire to overcome the limits of human biology. Yet beyond the ancient fascination with immortality lies a more fundamental medical question: can humans not only live longer, but live better?
That question is now moving from the realm of imagination into the laboratory. Modern longevity medicine is no longer focused on the unrealistic pursuit of eternal life. Instead, it seeks to understand the biological mechanisms of aging and develop interventions that can delay age-related decline, prevent chronic diseases, and extend healthspan.
At BIO Asia–Taiwan 2026 in Taipei, Alex Zhavoronkov, Founder, CEO and CBO of Insilico Medicine, argued that longevity medicine has entered a pivotal stage of transformation. In an exclusive interview with GeneOnline, Zhavoronkov discussed how the convergence of GLP-1 therapies, AI-powered drug discovery, aging biomarkers, and next-generation pharmaceutical strategies is driving the development of longevity therapeutics and redefining how medicine approaches aging.
“Right now there are multiple factors that converge for the benefit of longevity biotechnology,” he said. “The number one factor is that now we actually see the first potential longevity therapeutics.”
Why Aging Has Become the Next Major Healthcare Challenge
Zhavoronkov mentions the rise of longevity medicine reflects a fundamental shift in healthcare priorities. Over the past century, medical innovation has transformed many once-fatal conditions into manageable diseases through advances in prevention, diagnostics, and therapeutics. As medicine continues to extend survival, however, a new challenge has emerged: addressing the biological processes that make people increasingly vulnerable to multiple chronic diseases later in life.
He argues that this represents the next frontier of medicine. Rather than treating diseases individually after they appear, researchers are increasingly exploring whether the underlying mechanisms of aging can become therapeutic targets themselves.
https://www.geneonline.com/alex-zhavoronkov-maps-a-path-forward-for-longevity-medicine/